MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.

被引：0
|
作者：
Nastoupil, Loretta J.
Song, Yuqin
Sehn, Laurie Helen
Sarkozy, Clementine
Zinzani, Pier Luigi
Silvestre, Antonio Salar
Zhang, Jun
Huang, Sha
Wang, Julie
Delarue, Richard
Trotman, Judith
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Inst Curie, Paris, France
[5] Univ Bologna, Bologna, Italy
[6] Hosp del Mar, Barcelona, Spain
[7] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China
[8] BeiGene USA Inc, San Mateo, CA USA
[9] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[10] Univ Sydney, Concord Repatriat Gen Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7590
引用
收藏
页数：1
相关论文
共 50 条
  • [1] MAHOGANY: A Phase 3 trial of Zanubrutinib (ZANU) plus anti-CD20 antibodies vs Lenalidomide plus Rituximab (L plus R) in patients (pts) with Relapsed or Refractory (R/R) Follicular or Marginal Zone Lymphoma (FL or MZL)
    Buske, C.
    Nastoupil, L. J.
    Song, Y.
    Sehn, L.
    Sarkozy, C.
    Zinzani, P. L.
    Salar, A.
    Zhang, J.
    Zhang, W.
    Fustier, P.
    Delarue, R.
    Trotman, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 305 - 306
  • [2] inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
    Sehn, Laurie Helen
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat Umar
    Lihou, Christine Francis
    Li, Di
    Scholz, Christian W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
    Vitolo, Umberto
    Merli, Michele
    Norasetthada, Lalita
    Wassenaar, Timothy Robert
    Martin, Eva Maria Donato
    Bobillo, Sabela
    Shen, Biyi
    Flink, Dina M.
    Zhu, Min
    Chandrasekharan, Soujanya
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Cordoba, Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat
    Lihou, Christine F.
    Cheng, Lulu
    Scholz, Christian W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
  • [5] LENALIDOMIDE PLUS RITUXIMAB IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 151 - 151
  • [6] inMIND: A Phase 3 Study of Tafasitamab plus Lenalidomide Add-On to Rituximab vs Placebo plus Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Trneny, Marek
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S402 - S402
  • [7] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
    Sehn, Laurie Helen
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Subcutaneous Epcoritamab with Rituximab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
    Falchi, Lorenzo
    Abrisqueta, Pau
    Nijland, Marcel
    Leppa, Sirpa
    Hutchings, Martin
    Holte, Harald
    Merryman, Reid W.
    Lugtenburg, Pieternella
    de Vos, Sven
    Cheah, Chan Y.
    Christensen, Jacob Haaber
    Arcaini, Luca
    Drott, Kristina
    Hellstrom, Mats
    Leslie, Lori A.
    Vitolo, Umberto
    Rana, Ali
    Abbas, Aqeel
    Wang, Liwei
    Minh Dinh
    Belada, David
    BLOOD, 2022, 140 : 1464 - 1466
  • [9] MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
    Andorsky, David J.
    Yacoub, Abdulraheem
    Bitran, Jacob D.
    Melear, Jason
    Brooks, Heather D.
    Foon, Kenneth A.
    Rizvi, Syed
    Llorente, Mary
    Li, Jiahui
    Sharman, Jeff P.
    BLOOD, 2016, 128 (22)
  • [10] A match-adjusted indirect treatment comparison of lenalidomide plus rituximab versus rituximab plus chemotherapy for relapsed and/or refractory follicular lymphoma.
    Fox, Christopher P.
    Arcaini, Luca
    Hernandez-Ilizaliturri, Grancisco
    Tabah, Ashley
    Parker, Christopher
    Jones, Jeffrey
    Abouzaid, Safiya
    Watkins, Claire
    Bachy, Emmanuel
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S29 - S30
12345